Why We're Watching Valeant

A lot of action surrounding Valeant Pharmaceuticals. Anders Keitz from the Real Money Fill or Kill team breaks down the latest headlines.
Author:
Publish date:

Shares of struggling Canadian drugmaker Valeant  (VRX) got an early jump ahead of the opening bell on news it rebuffed a takeover bid by TPG and Takeda Pharmaceuticals. Both companies were reportedly looking at a joint takeover proposal before Joseph Papa was named Valeant CEO late last month. The report offer seems to be encouraging investors who lost hope in the drugmaker, after months of controversy surrounding price hikes, as well as bookkeeping irregularities surrounding Valeant's former partnership with mail-order pharmacy Philidor.

This article was written by a staff member of TheStreet.